Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week
- PMID: 36007992
- DOI: 10.1016/j.jacc.2022.06.019
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week
Abstract
This study reviews ancestral differences in the genetics of the LPA gene, risk categories of elevated lipoprotein(a) [Lp(a)] as defined by guidelines, ancestry-specific Lp(a) risk, absolute and proportional risk, predictive value of risk thresholds among different ancestries, and differences between laboratory vs clinical accuracy in Lp(a) assays. For clinical decision-making, the preponderance of evidence suggests that the predictive value of Lp(a) does not vary sufficiently to mandate the use of ancestry-specific risk thresholds. This paper interprets the literature on Lp(a) and ancestral risk to support: 1) clinicians on understanding cardiovascular disease risk in different ancestral groups; 2) trialists for the design of clinical trials to ensure adequate ancestral diversity to support broad conclusions of drug effects; 3) regulators in the evaluation of the design and interpretation of results of Lp(a)-lowering trials with different Lp(a) inclusion thresholds; and 4) clinical laboratories to measure Lp(a) by assays that discriminate risk thresholds appropriately.
Keywords: ancestry; aortic stenosis; atherosclerosis; lipoprotein(a); threshold.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This study was supported in part by the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL159156, Dr Tsimikas). Dr Tsimikas is a co-inventor and receives royalties from patents owned by the University of California San Diego and is a co-founder and has an equity interest in Oxitope, Inc and its affiliates, Kleanthi Diagnostics, LLC and Covicept Therapeutics, Inc; and has a dual appointment at the University of California San Diego and Ionis Pharmaceuticals. Dr Marcovina is a consultant for Roche Diagnostics, Denka Seiken, and Novartis; and receives research support from contracts between Amgen and Medpace.
Similar articles
-
Lipoprotein(a) in clinical practice: A guide for the clinician.Prog Cardiovasc Dis. 2023 Jul-Aug;79:28-36. doi: 10.1016/j.pcad.2023.07.006. Epub 2023 Jul 27. Prog Cardiovasc Dis. 2023. PMID: 37516261 Review.
-
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research.Eur J Prev Cardiol. 2024 May 11;31(7):903-914. doi: 10.1093/eurjpc/zwae032. Eur J Prev Cardiol. 2024. PMID: 38253342 Review.
-
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective.Atherosclerosis. 2022 May;349:7-16. doi: 10.1016/j.atherosclerosis.2022.04.015. Atherosclerosis. 2022. PMID: 35606078 Review.
-
Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study.Acta Cardiol. 2023 Jul;78(5):536-542. doi: 10.1080/00015385.2022.2031377. Epub 2022 Feb 10. Acta Cardiol. 2023. PMID: 35144517
-
Lipoprotein(a): from Causality to Treatment.Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22. Curr Atheroscler Rep. 2024. PMID: 38252372 Free PMC article. Review.
Cited by
-
Exploring the Effect of Thyroid Hormone on Serum Lipoprotein (a) Levels in Patients With Thyroid Hormone Dysfunction: A Systematic Review.Cureus. 2024 Aug 7;16(8):e66361. doi: 10.7759/cureus.66361. eCollection 2024 Aug. Cureus. 2024. PMID: 39246961 Free PMC article. Review.
-
Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk.Curr Diab Rep. 2024 Jul;24(7):167-172. doi: 10.1007/s11892-024-01543-5. Epub 2024 May 28. Curr Diab Rep. 2024. PMID: 38805111 Review.
-
Lipoprotein(a) and Effects of Diet: Time for Reassessment.Nutrients. 2025 May 19;17(10):1714. doi: 10.3390/nu17101714. Nutrients. 2025. PMID: 40431454 Free PMC article. Review.
-
Association between hepatic steatosis and lipoprotein(a) levels in non-alcoholic patients: A systematic review.Indian J Gastroenterol. 2024 Jun;43(3):536-547. doi: 10.1007/s12664-023-01457-2. Epub 2023 Dec 1. Indian J Gastroenterol. 2024. PMID: 38036914
-
Lipoprotein(a) as a predictor of mortality in hospitalised patients with ischaemic heart disease.Front Endocrinol (Lausanne). 2025 Jul 22;16:1541712. doi: 10.3389/fendo.2025.1541712. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40766294 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous